| Dr Narmadan Akileswaran Kumarasamy, MD | |
|
30 Prospect Ave, Radiology Dept, Hackensack, NJ 07601-1915 | |
| (000) 000-0000 | |
| Not Available |
| Full Name | Dr Narmadan Akileswaran Kumarasamy |
|---|---|
| Gender | Male |
| Speciality | Diagnostic Radiology |
| Experience | 13 Years |
| Location | 30 Prospect Ave, Hackensack, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083900575 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2085R0202X | Radiology - Diagnostic Radiology | 25MA10054600 (New Jersey) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hackensack University Medical Center | Hackensack, NJ | Hospital |
| Palisades Medical Center | North bergen, NJ | Hospital |
| Hackensack Meridian Health Pascack Valley Medical | Westwood, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| New Century Imaging Llc | 4082517370 | 49 |
| Imaging North, Llc | 9133514987 | 31 |
| Hackensack Radiology Group Pa | 9830096361 | 42 |
News Archive
Mercury is an incredibly stubborn toxin. Once it is emitted from the smokestacks of coal-fired power plants, among other sources, the gas can drift through the atmosphere for up to a year before settling into oceans and lakes.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
AultCare has been using patient telemonitoring for six years and has, in partnership with Cardiocom, released a white paper entitled, "AultCare Sees Positive Results from Cardiocom Program."
A large European research consortium headed by the University of Twente is to receive grants of more than five million euros, predominantly from the EU, to develop a new imaging device for the diagnosis of breast cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 7 days ago
| Entity Name | New Century Imaging Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710909262 PECOS PAC ID: 4082517370 Enrollment ID: O20041209000031 |
News Archive
Mercury is an incredibly stubborn toxin. Once it is emitted from the smokestacks of coal-fired power plants, among other sources, the gas can drift through the atmosphere for up to a year before settling into oceans and lakes.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
AultCare has been using patient telemonitoring for six years and has, in partnership with Cardiocom, released a white paper entitled, "AultCare Sees Positive Results from Cardiocom Program."
A large European research consortium headed by the University of Twente is to receive grants of more than five million euros, predominantly from the EU, to develop a new imaging device for the diagnosis of breast cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 7 days ago
| Entity Name | Hackensack Radiology Group Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306864343 PECOS PAC ID: 9830096361 Enrollment ID: O20060417000055 |
News Archive
Mercury is an incredibly stubborn toxin. Once it is emitted from the smokestacks of coal-fired power plants, among other sources, the gas can drift through the atmosphere for up to a year before settling into oceans and lakes.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
AultCare has been using patient telemonitoring for six years and has, in partnership with Cardiocom, released a white paper entitled, "AultCare Sees Positive Results from Cardiocom Program."
A large European research consortium headed by the University of Twente is to receive grants of more than five million euros, predominantly from the EU, to develop a new imaging device for the diagnosis of breast cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 7 days ago
| Entity Name | Imaging North, Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1245835131 PECOS PAC ID: 9133514987 Enrollment ID: O20220315001152 |
News Archive
Mercury is an incredibly stubborn toxin. Once it is emitted from the smokestacks of coal-fired power plants, among other sources, the gas can drift through the atmosphere for up to a year before settling into oceans and lakes.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
AultCare has been using patient telemonitoring for six years and has, in partnership with Cardiocom, released a white paper entitled, "AultCare Sees Positive Results from Cardiocom Program."
A large European research consortium headed by the University of Twente is to receive grants of more than five million euros, predominantly from the EU, to develop a new imaging device for the diagnosis of breast cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Narmadan Akileswaran Kumarasamy, MD 130 Kinderkamack Rd Ste 200, River Edge, NJ 07661-1931 Ph: (201) 488-2660 | Dr Narmadan Akileswaran Kumarasamy, MD 30 Prospect Ave, Radiology Dept, Hackensack, NJ 07601-1915 Ph: (000) 000-0000 |
News Archive
Mercury is an incredibly stubborn toxin. Once it is emitted from the smokestacks of coal-fired power plants, among other sources, the gas can drift through the atmosphere for up to a year before settling into oceans and lakes.
Researchers at Adaptimmune Limited and the University of Pennsylvania School of Medicine, have announced the approval of an Investigational New Drug (IND) application from the US Food and Drug Administration (FDA) and opening for enrolment of the first ever study using patients' cells carrying an engineered T cell receptor to treat HIV (SL9 HA-GAG-TCR). The trial may have important implications in the development of new treatments for HIV potentially slowing – or even preventing – the onset of AIDS.
AultCare has been using patient telemonitoring for six years and has, in partnership with Cardiocom, released a white paper entitled, "AultCare Sees Positive Results from Cardiocom Program."
A large European research consortium headed by the University of Twente is to receive grants of more than five million euros, predominantly from the EU, to develop a new imaging device for the diagnosis of breast cancer.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, driven by the launches of several promising emerging therapies, the prostate cancer drug market will experience robust growth over the next decade, increasing from $3.6 billion in 2010 to $10.1 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.
› Verified 7 days ago
Dr. Christopher I Song, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave Radiology Dept, Hackensack, NJ 07601 Phone: 551-996-2200 | |
Dr. George J Ferrone, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Radiology Dept, Hackensack, NJ 07601 Phone: 000-000-0000 | |
Dr. Jaskirat Singh Virk, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Radiology Dept, Hackensack, NJ 07601 Phone: 000-000-0000 | |
Dr. David John Monoky, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Radiology Dept, Hackensack, NJ 07601 Phone: 000-000-0000 | |
Jacquelyn N Copeland, MD Radiology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave Radiology Dept, Hackensack, NJ 07601 Phone: 551-996-2200 | |
Oreoluwa Ojutiku, M.D. Radiology Medicare: Accepting Medicare Assignments Practice Location: 30 Prospect Ave, Hackensack, NJ 07601 Phone: 201-996-2200 Fax: 201-489-2812 |